Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 11:15 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2113–2136 of 2,670 matching trials from the live ClinicalTrials.gov search.

Filters: Sponsor: University of San Francisco Clear all

Conditions: Non-melanomatous Skin Cancer
Interventions: celecoxib; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 2
States / cities: San Francisco, California • New York, New York

Conditions: Pancreatic Cancer
Interventions: bevacizumab, cisplatin, gemcitabine hydrochloride; Biological · Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Sarcoidosis, Sarcoidosis, Pulmonary
Interventions: Observational Study; Other
Lead sponsor: National Jewish Health; Other
Eligibility: 18 Years to 85 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Subarachnoid Hemorrhage, Subdural Hematoma, Traumatic Brain Injury, Ischemic Stroke, Fever, Intracerebral Hemorrhage
Interventions: Bromocriptine 5 MG, Acetaminophen 650 MG; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 100 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: San Francisco, California

Conditions: Patient Safety
Interventions: Academic detailing and audit and feedback intervention; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Not listed
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Gynecologic Cancer
Interventions: Digital Health Mobile App, Virtual Support Group, Health Coaching, FitBit, Handouts; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Non-small Cell Lung Cancer
Interventions: Trametinib; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Smoking Cessation, Smoking Cessation Counseling Ability and Practice, Smoking Cessation Counselling, Lung Cancer Screening
Interventions: CONNECT Intervention for multilingual populations, Saliva Sample, Interview; Behavioral · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 50 Years to 80 Years
Enrollment: 439 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Post Traumatic Stress Disorder
Interventions: Personalized Attention Bias Training, Neutral Attention Training Condition, Non-Personalized Attention Bias Training; Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 689 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Pulmonary Hypertension
Interventions: Magnetic resonance Imaging; Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hypoxia
Interventions: Pulse oximeter; Device
Lead sponsor: Nihon Kohden; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Stress, Psychological, Telomere Shortening, Stress Reaction
Interventions: Reclaiming Nature Intervention; Behavioral
Lead sponsor: Charlotte Tate; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Retinitis Pigmentosa
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 13 Years and older
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Preterm Premature Rupture of the Membranes, Physical Activity
Interventions: Moderate Activity; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older · Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: San Diego, California

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: EGCG 300 mg + Nintedanib, EGCG 300 mg + Pirfenidone, Placebo 2 capsules + Nintedanib or Pirfenidone, EGCG 600 mg + Nintedanib, EGCG 600 mg + Pirfenidone, Placebo 4 capsules + Nintedanib or Pirfenidone; Combination Product
Lead sponsor: Hal Chapman; Other
Eligibility: 40 Years to 85 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 7
States / cities: San Francisco, California • Boston, Massachusetts • Ann Arbor, Michigan + 4 more

Conditions: Long COVID, Post-Acute Sequela of COVID-19, Post-Acute COVID-19
Interventions: AER002, Placebo; Drug · Other
Lead sponsor: Michael Peluso, MD; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Optic Nerve Injuries, Sellar Tumor, Skull Base Neoplasms
Interventions: Optic Nerve Stimulation; Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Diabetes Mellitus
Interventions: Automated Telephone Nutrition Support; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 85 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Oakland, California

Conditions: Acute Myeloid Leukemia, Myelodysplasia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Multiple Myeloma, Lymphomas, Low-grade NHL and Chronic Lymphocytic Leukemia
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Stress, Mindfulness, Cognitive Change
Interventions: Enhanced Stress Resilience Training (ESRT), Active Control; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 64 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Prostate Cancer
Interventions: Ga-68 labeled PSMA-11 PET; Drug
Lead sponsor: Thomas Hope; Other
Eligibility: 18 Years and older · Male only
Enrollment: 346 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hemophagocytic Lymphohistiocytoses
Interventions: Ruxolitinib, Etoposide, Dexamethasone, Non-interventional Imaging, Research Biopsy, Biospecimen Collection; Drug · Procedure
Lead sponsor: Jerry Lee, MD, MSc, MPhil; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 4
States / cities: Irvine, California • Sacramento, California • San Diego, California + 1 more

Conditions: Asthma
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Patients With Residual or Reccurent EGFRvIII+ Glioma
Interventions: CART-EGFRvIII T cells; Biological
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 2
States / cities: San Francisco, California • Philadelphia, Pennsylvania

Search by objective public record fields.

Celecoxib in Preventing Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome

Gemcitabine, Cisplatin, and Bevacizumab in Treating Patients With Metastatic Pancreatic Cancer

Epigenetic Regulation of Altered T-cell Immunity in Sarcoidosis

Efficacy of Bromocriptine For Fever Reduction in Acute Neurologic Injury

An Intervention to Impact Cardiovascular Implantable Electronic Device Lead Models Implanted in Veterans

Exercise and Movement to Enhance Resiliency in Cancer Patients

Trametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell Lung Cancer

Evaluating the Impact of CONNECT in a Multilingual Population

Remotely Resolving Psychological Stress (Remote RePS)

Cardiac MRI in Pulmonary Hypertension

Accuracy of Pulse Oximeters With Profound Hypoxia At Rest (NIHO16)

Biological and Behavioral Outcomes of Community Nature Walks

Retinal Imaging in Patients With Inherited Retinal Degenerations

A Comparison of Bed Rest Versus Moderate Activity in Preterm Premature Rupture of Membranes (PPROM)

Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients

Anti-SARS-CoV-2 Monoclonal Antibodies for Long COVID (COVID-19)

Optic Nerve Stimulation To Prevent Visual Deficits After Endoscopic Cranial Approaches

Automated Telephone Nutrition Support

Pilot Study of Reduced-Intensity Umbilical Cord Blood Transplantation in Adult Patients Wtih Advanced Hematopoietic Malignancies

Enhanced Stress Resilience Training for Residents

Gallium-68 PSMA-11 Positron Emission Tomography (PET) Imaging in Patients With Biochemical Recurrence

Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)

Mechanistic Insights From Bronchoscopy Airway Samples

Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ Glioblastoma